Stock APTOSE BIOSCIENCES
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Aptose Biosciences Nasdaq

Equities

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aptose Announces Results from Annual and Special Meeting of Shareholders
AQ
Transcript : Aptose Biosciences Inc. - Shareholder/Analyst Call
Aptose Biosciences : 2024 EHA Poster – Safety and Efficacy of Tuspetinib as Monotherapy and Combined with Venetoclax in a Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
PU
Aptose Biosciences : 2024 EHA Poster – Tuspetinib Retains Nanomolar Potency Against AML Cells Engineered to Express the NRAS G12D Mutation or Selected for Resistance to Venetoclax
PU
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
AQ
Aptose Biosciences Inc. Presents Tuspetinib Clinical and Preclinical Findings At European Hematology Association 2024 Hybrid Congress
CI
HC Wainwright Adjusts Price Target on Aptose Biosciences to $7 From $23, Maintains Buy Rating
MT
Aptose Closes U$4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MT
Aptose Biosciences Down 14% In US Premarket As Plans to Raise Near $4.4 Million Via Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MT
Aptose Biosciences Brief: Announcing US$4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MT
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AQ
APTE BIOS : Earnings Presentation
PU
APTE BIOS : Aptose 1Q Earnings Presentation
PU
Transcript : Aptose Biosciences Inc., Q1 2024 Earnings Call, May 14, 2024
Aptose Biosciences Q1 Net Loss Falls, on Lower Expenses
MT
Aptose Biosciences: Q1 Earnings Snapshot
AQ
Aptose Biosciences Brief: Also Notes TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML
MT
Aptose Biosciences Brief: Notes TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to FDA During Q1 and is Now Being Activated at Clinical Sites
MT
Aptose Biosciences Brief: Q1 Net Loss per share, Basic and diluted US$(0.73)
MT
Aptose Reports Results for the First Quarter 2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APS Stock
  4. Stock
  5. News Aptose Biosciences